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a b s t r a c t
The optimal salvage therapy for patients with relapsed Burkitt lymphoma is unknown. Bone marrow
necrosis is an underreported (o1% of bone marrow failures). Numb chin syndrome is another rare
syndrome associated with aggressive malignancies. Survival of these syndromes is dictated by the
underlying disease and is usually dismal. Our 35-year-old patient experienced an early relapse of Burkitt
lymphoma accompanied by syndromes, achieved second complete remission and underwent allogeneic
stem cell transplantation. He remains alive and well 42 years after the transplant. To our knowledge,
this is the longest reported survival of the two syndromes in the setting of BL relapse.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Case report
We present a case of a man who initially presented at age of 34
with complaints of cough, malaise, fever and bone pain, thrombo-
cytopenia 35103/mL, anemia (hematocrit 23.9%) and leukocytosis
13.7103/mL with 16% bands, but no other immature cells. Given
his outdoor lifestyle and exposures an extensive infectious disease
work up was performed including Lyme disease, Rocky Mountain
Spotted Fever, anaplasmosis, babesiosis was negative. With wor-
sening clinical status and LDH of 2730 IU/L the patient had a bone
marrow (BM) biopsy performed. The bone marrow was inaspir-
able, however core biopsy revealed 100% cellularity and blastic-
looking cells with high nuclear to cytoplasmic ratio, prominent
nucleoli, basophilic cytoplasm and cytoplastic vacuoles (see Fig. 1A
and B). Interphase ﬂuorescence in situ hybridization (FISH)
revealed 72/100 nuclei carried an IGH@-CMYC rearrangement
further conﬁrming a high-grade Burkitt lymphoma (BL), no rear-
rangements were seen using BCL6 and BCL2 probes. Polymerase
chain reaction showed IgH monoclonal band. At the same time CT
scan showed a 4.24.9 cm2 mass arising from the medial wall of
the cecum, involving terminal ileum, an adjacent 5.03.7 cm2
lymphnode mass was seen in the mesentery with extensive soft
tissue nodularities in the omentum. His cerebrospinal ﬂuid
showed normal protein and glucose, negative cytology (2
specimens2–3 mL) and ﬂow (sensitivity 104).
The patient began CODOX-M/IVAC with rituximab [2]. PET and
BM after 2 cycles showed complete remission (CR) and this was
conﬁrmed 3 and 6 months later after he completed the full
treatment course. There was no delay in administration of each
cycle (average: 19 days, 16–21). Eight months after therapy
completion he developed ﬂu-like symptoms, WBC 9.1103/mL,
mild anemia and thrombocytopenia 23103/mL, uric acid 4.7, LDH
1977 IU/L. CT scans were negative and BM showed relapse (see
Fig. 1C and D). The patient complained of submental numbness,
CSF sampling was negative3 by cytology and ﬂow (2–3 mL
each), MRI of the brain with focus on cranial nerves was negative
for leptomeningeal involvement, his condition was concluded as
numb chin syndrome (NCS). He received EPOCH-R with IT metho-
trexate 15 mg (on day 1) and IT cytarabine 100 mg (at least 72 h
after MTX) [3]. After the ﬁrst cycle the patient's marrow showed
80% cellularity and a large area of necrotic tumor cells occupying
60–70% of the total marrow space consistent with bone marrow
necrosis (BMN), the remaining 30–40% of marrow comprised of
viable tumor cells, which were intermediate in cell size with round
nuclei, indistinct nucleoli and scant amount of cytoplasm (see
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Fig. 1E and F). CD20 was strongly positive in both viable and
necrotic tumor cells. Subsequent cycles were initiated at the ﬁrst
sign of hematological recovery (plts475,000/mL, ANC4500/mL).
Second CR was conﬁrmed after second cycle (PET and BM).
Aggressive prophylaxis with antibiotics, antifungals, antivirals,
and against pneumocystis together with G-CSF were used. Fourth
cycle was delayed by an episode of respiratory infection with
parainﬂuenza 3, which was treated with IVIG (dose 500 mg/kg).
After 6 cycles (average 16.6 days, 15–20) the patient underwent 10/10
HLA matched unrelated donor transplant (CMV: Rþ/D) with
Fig. 1. (A) Bone marrow core biopsy showing 100% cellularity with diffuse Burkitt lymphoma inﬁltration effacing the normal marrow architecture, H&E stain. Majority of the
cells were blastic-looking with high nuclear to cytoplasmic ratio, two to three prominent nucleoli, basophilic cytoplasm and cytoplastic vacuoles. Reticulin stain showed mild
reticulin ﬁbrosis. The neoplastic cells were negative for CD3, CD10, CD34, CD117, CD138, MPO, and TdT while they were strongly positive for CD20 (B) and positive for CD79a,
BCL2, BCL6, PAX5, and Ki67 showed positivity in nearly 100% of cells. (C) Bone marrow biopsy showing Burkitt lymphoma inﬁltration, H&E stain. (D) Majority of the cells
were blastic-looking with high nuclear to cytoplasmic ratio, two to three prominent nucleoli, basophilic cytoplasm and cytoplastic vacuoles. (E) Bone marrow core biopsy
showing necrotic Burkitt lymphoma after ﬁrst cycle of salvage chemotherapy. (F) Necrotic area with ghost outlines of intermediate-sized cells, which were positive for CD20.
(G) Bone marrow core biopsy showing necrotic Burkitt lymphoma one year after allogeneic stem cell transplantation. 40% cellular marrow with maturing adequate trilineage
hematopoiesis and 2/3 of the biopsy contained. (H) The necrotic area showed again many ghost outlines of intermediate-sized cells, which were positive for CD20, but
negative for other markers CD3, PAX5, BCL-2, BCL-6, CD10, and Ki-67.
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thiotepa/ﬂudarabine/melphalan, posttransplant cyclophosphamide
and sirolimus [4], which was tapered rapidly within 4 months. He
remained asymptomatic and GVHD free at one year after his
transplant: WBC 6.7103/mL, HCT 37.9%, and platelets 260103/
mL. BM from the site where necrosis was present at relapse showed
40% cellular marrow with maturing adequate trilineage hematopoi-
esis and 23 of the biopsy contained a necrotic area with many ghost
outlines of intermediate-sized cells, which were positive for CD20,
but negative for other markers (see Fig. 1G and H). The patient's
counts and chimerism (497% donor BM and blood) were stable. For
profound hypogammaglobulinemia and frequent respiratory infec-
tions he has received monthly IVIG. He is currently alive and well
2 years after his transplant. To our knowledge, this is the longest
reported survival of BMN in setting of BL relapse.
2. Discussion
The optimal salvage strategy for BL patients with a partial
remission or relapsed disease, is unknown. Combination salvage
chemotherapy is usually attempted, but very few to no patients
with BL achieve a meaningful response regardless of the chemother-
apy agents used [1]. Autologous or allogeneic stem cell transplanta-
tion (ASCT or AlloSCT) represents a logical next step in consolidation
of response; however, published data addressing high-dose therapy
in BL are confounded by selection bias and the data is limited to
subgroups of retrospective analyses [5–7], and case reports [8].
Chemosensitivity and disease status at the time of transplant
determine the outcome. While clinical trial participation is war-
ranted, due to time constrains this is very often not practical for
patients and their physicians.
Given the presence of BMN an AlloSCT was chosen for our
patient. BMN is a rare and poorly understood complication of
aggressive hematological malignancies with dismal survival ran-
ging from 1 to 4 months. Retrospective data associated upto 15% of
BMNs with lymphoma [10]. Different sites were used for BM
biopsies and we cannot conﬁrm whether BMN was present before
salvage therapy. We however conﬁrmed that BMN was persistent
at least one year posttransplant proving the point that bone
marrow can undergo remodeling, but is a prolonged process [9].
PET scan and MRI were not helpful in identifying the extent of the
BMN. Associations with bone marrow ﬁbrosis were seen, but
historically these were limited to patients with underlying mye-
loproliferative neoplasms [9,10]. We did not see any increase
reticulin. The ﬁnding of persistent BMN represents a therapeutic
dilemma. Successful use of rituximab has been previously reported
for PTLD related BMN [11]. Rituximab was discussed with the
patient, but not used as he remains clinically stable with normal
counts and he requires IVIG replacement for frequent respiratory
infections.
NCS is a rare syndrome. In case series of NCS 14–47% were
associated with of lymphoproliferative disorders [reviewed in
[12]]. Survival is usually dictated by the underlying disease and
short in the setting of aggressive malignancies. Since NCS may be a
manifestation of an underlying malignancy it has to be taken
seriously. Though imaging and CSF studies were negative in our
patient the specimens collected were not high volume and we
treated the patient with prophylactic IT methotrexate and cytar-
abine. Residual NCS is still present42 years since initial presenta-
tion. We did not identify the actual etiology, but differential
diagnosis includes impingement with lymphoma, BMN, previous
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